| Dov A. Goldstein |
Dov A. Goldstein currently works at ADMA Plasma Biologics, Inc., as Director, Gain Therapeutics, Inc., as Independent Director from 2021, Coya Therapeutics, Inc., as Independent Director from 2021, and BioAge Labs, Inc., as Chief Financial Officer from 2021. Dr. Goldstein also formerly worked at MIA Dynamics Motors Ltd., as Chairman & Chief Executive Officer from 2006 to 2014, RIGImmune, Inc., as President, CEO, Treasurer & Director from 2018 to 2020, NeuBase Therapeutics, Inc., as Chairman from 2022 to 2025, Esperion Therapeutics, Inc., as Independent Director from 2008 to 2019, Cempra Pharmaceuticals, Inc., as Director from 2009 to 2013, Topaz Pharmaceuticals, Inc., as Director, ADMA Biologics, Inc., as Independent Non-Executive Director from 2007 to 2020, Cempra, Inc., as Director from 2008 to 2011, HealthCare Ventures LLC, as Director-Venture Analysis, Global Pay (P.C.S) Ltd., as Director, Scerene Healthcare, Inc., as Director, Durata Therapeutics, Inc., as Interim Co-President & Independent Director from 2009 to 2012, Neubase Therapeutics, Inc., as Director, Geom Therapeutics, Inc., as Director, Vicuron Pharmaceuticals LLC, as Chief Financial Officer & Executive Vice President from 2001 to 2005, Aisling Capital LLC, as Operating Partner from 2006 to 2019, Schrödinger, Inc., as Chief Financial Officer from 2017 to 2018, RCMC Capital LLP, as Managing Partner from 2014 to 2019, Loxo Oncology, Inc., as Chief Financial Officer from 2014 to 2015, and Indapta Therapeutics, Inc., as Chief Financial & Business Officer from 2020 to 2021. Dr. Goldstein received his undergraduate degree in 1990 from Stanford University, Masters Business Admin degree from Columbia Business School, and doctorate degree from Yale School of Medicine. |
| Ann Neale |
Ann Neale currently works at BioAge Labs, Inc., as Chief Development Officer from 2021, Principia Biopharma, Inc., as Senior Vice President-Development Operations, and Science 37, Inc., as SVP Clinical Operations & Patient Affairs from 2017. Ms. Neale also formerly worked at Saegis Pharmaceuticals, Inc., as Vice President-Clinical Operations from 2004 to 2006. Ms. Neale received her undergraduate degree from the University of Minnesota. |
| Rusty Montgomery |
Rusty Montgomery currently works at BioAge Labs, Inc., as Senior Vice President-Research from 2023. Dr. Montgomery also formerly worked at Viridian Therapeutics, Inc., as Director-Research. Dr. Montgomery received his undergraduate degree from the University of Oklahoma and doctorate degree from The University of Texas Southwestern Medical Center. |
| Eric Morgen |
Eric Morgen is the founder. Dr. Morgen is the Chief Operating Officer & Director at BioAge Labs, Inc., founded in 2015. Dr. Morgen attended the University of Toronto and obtained an undergraduate degree. |
| Peng Leong |
Peng Leong currently works at BioAge Labs, Inc., as Chief Business Officer from 2019. Dr. Leong also formerly worked at Kazia Therapeutics Ltd., as Chief Business Officer from 2016 to 2018. Dr. Leong received his doctorate degree from the University of Toronto and Masters Business Admin degree from the University of California, Berkeley. |
| B. J. Sullivan |
B. J. Sullivan currently works at BioAge Labs, Inc., as Chief Strategy Officer from 2023. Dr. Sullivan received his undergraduate degree from Princeton University and doctorate degree from David Geffen School of Medicine. |
| Jean-Pierre Garnier |
Jean-Pierre Garnier currently works at Cellectis SA, as Non-Executive Chairman from 2020, BioAge Labs, Inc., as Chairman from 2024, Carrier Corp., as Director, Carrier Global Corp., as Independent Director, and Advent International LLC, as Operating Partner. Dr. Garnier also formerly worked at Smithkline Beecham Plc, as Chief Executive Officer from 2000 to 2001, GSK Plc, as Chief Executive Officer & Executive Director from 2000 to 2008, Pierre Fabre SA, as Chief Executive Officer from 2008 to 2010, NormOxys, Inc., as Chairman, Alzheon, Inc., as Chairman from 2015 to 2019, ABIONYX Pharma SA, as Chairman, Carmat SA, as Non-Executive Chairman from 2018 to 2022, Idorsia Ltd., as Chairman from 2017 to 2020, Idorsia Pharmaceuticals Ltd., as Non-Executive Chairman from 2017 to 2020, United Technologies Corp., as Independent Director from 1997 to 2020, Radius Health, Inc., as Independent Director from 2015 to 2022, Renault SA, as Independent Director from 2010 to 2017, Actelion Ltd., as Director in 2017, Pierre Fabre Participations SAS, as Director in 2010, Cerenis Therapeutics, Inc., as Director in 2011, Weill Cornell Medical College, as Director, Max Planck Institute For Biophysical Chemistry, as Director from 2013 to 2019, Schering-Plough Corp., as President, e.Nvizion Communications Group Ltd., as President from 1983 to 2006, Newman's Own Foundation, as Trustee, Quaker Partners Management LP, as Advisor, and Max Planck Florida Institute for Neuroscience, as Trustee. Dr. Garnier received his Masters Business Admin degree in 1974 from Stanford University and graduate degree and doctorate degree from Louis Pasteur University. |
| Paul D. Rubin |
Paul D. Rubin currently works at BioAge Labs, Inc., as Chief Medical Officer & Executive VP-Research from 2020. Dr. Rubin also formerly worked at Critical Therapeutics, Inc., as President & Chief Executive Officer from 2002 to 2007, Resolvyx Pharmaceuticals, Inc., as President & Chief Executive Officer from 2007 to 2009, Abbott Laboratories, as Vice President-Immunology & Endocrinology from 1987 to 1993, Sumitomo Pharma America, Inc., as Executive Vice President-Research & Development from 1996 to 2002, XOMA Royalty Corp., as Chief Medical Officer, SVP-Research & Development from 2012 to 2016, Funxional Therapeutics Ltd., as Chief Medical Officer in 2011, GlaxoSmithKline LLC, as Vice President-Worldwide Clinical Pharmacology from 1993 to 1996, and Viridian Therapeutics, Inc., as Executive Vice President-Research & Development from 2017 to 2019. Dr. Rubin received his undergraduate degree from Occidental College and doctorate degree from Rush Medical College. |
| Kristen Fortney |
Kristen Fortney is the founder of BioAge Labs, Inc. and holds the title of President, Chief Executive Officer & Director since 2015. Dr. Fortney earned a doctorate from the University of Toronto. |
| Michael H. Davidson |
Michael H. Davidson was the founder of Omthera Pharmaceuticals, Inc. (2008, Chief Medical Officer), Chicago Center for Clinical Research (1987, President & Chief Executive Officer), Corvidia Therapeutics, Inc. (2016, Co-Chief Scientific & Medical Officer), and Trofi Nutritionals, Inc. (2021, Director & Chief Scientific Officer). Dr. Davidson is also the founder of SonoThera, Inc. Dr. Davidson is currently the Chief Executive Officer & Executive Director at NewAmsterdam Pharma BV, NewAmsterdam Pharma Holding BV, NewAmsterdam Pharma Corp., and. NewAmsterdam Pharma Co. NV since 2020; Independent Director at Tenax Therapeutics, Inc. since 2021; Director at Sonogene LLC; Independent Non-Executive Director at Silence Therapeutics Plc; Director-Lipid Clinic & Professor at The University of Chicago; Director at Preventive Cardiology Institute, Inc.; Director at Abcentra, Inc. since 2021; Director at Midwest Lipid Association; Director at Inositec AG since 2020; Director at Jocasta Neuroscience, Inc.; Director at NanoPhoria Srl; Independent Director at BioAge Labs, Inc. starting in 2024; Member at American College of Chest Physicians; Member at American College of Cardiology Foundation; and Professor at The University of Chicago Department of Medicine since 2007. Former positions include Independent Director at ABIONYX Pharma SA (2015-2019), Independent Director at Caladrius Biosciences, Inc., Director at Cerenis Therapeutics, Inc. (2015-2019), and President at National Lipid Association (2010-2011). Education includes an undergraduate degree from Northwestern University and a doctorate from The Ohio State University College of Medicine. |
| James Irvin Healy |
Dr. James I. Healy is an Independent Director at BioAge Labs, Inc., an Independent Non-Executive Director at Rapport Therapeutics, Inc., an Independent Director at Arrivent BioPharma, Inc., a Chairman at Y-mAbs Therapeutics, Inc., an Independent Director at Natera, Inc., a Managing Partner at Sofinnova Investments, Inc., a Managing Partner at Sofinnova Investments, Inc., a General Partner at Sofinnova Venture Partners VII LP, a Managing Partner at Sofinnova Management VI LLC and a Managing Partner at Sofinnova Management VII LLC. He is on the Board of Directors at BioAge Labs, Inc., Rapport Therapeutics, Inc., Arrivent BioPharma, Inc., Natera, Inc., Atsena Therapeutics, Inc., Iterum Therapeutics International Ltd., Iterum Therapeutics US Holding Ltd. and Sorbent Therapeutics, Inc.
Dr. Healy was previously employed as a Lead Independent Director by Bolt Biotherapeutics, Inc., an Independent Director by Karuna Therapeutics, Inc., a Chairman by CinCor Pharma, Inc., an Independent Director by Iterum Therapeutics Plc, an Independent Director by Edge Therapeutics, Inc., an Independent Director by Ascendis Pharma A/S, an Independent Non-Executive Director by NuCana Plc, an Independent Director by Coherus BioSciences, Inc., an Independent Director by ObsEva SA, a Vice Chairman by Auris Medical AG, a Vice Chairman by Auris Medical Holding AG /Old/, an Independent Director by Durata Therapeutics, Inc., an Independent Non-Executive Director by Amarin Corp. Plc, a Chairman by Hyperion Therapeutics, Inc., an Independent Director by Anthera Pharmaceuticals, Inc., an Independent Director by KaloBios Pharmaceuticals, Inc., an Independent Director by InterMune, Inc., a Manager by Advanced Corneal Systems, Inc., an Associate by Sanderling Management CO LLC.
He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from Stanford University School of Medicine. |
| Vijay S Pande |
Vijay S Pande is the founder of Globavir Biosciences, Inc. (2014). Current jobs include Director at Devoted Health, Inc. (2018), Director at Insitro, Inc. (2020), Director at Ciitizen Corp. (2019), Director at Nautilus Subsidiary, Inc., Director at Akasa, Inc., and Independent Director at BioAge Labs, Inc. (2017). Former jobs include Independent Director at Nautilus Biotechnology, Inc. (2021-2025), Director at Rigetti & Co., Inc., Director at Aria Pharmaceuticals, Inc., Professor at Stanford University, and General Partner at AH Capital Management LLC (2015-2025). Education includes a doctorate from Massachusetts Institute of Technology and an undergraduate degree from Princeton University. |
| Rekha Hemrajani |
Rekha Hemrajani currently works at MaxCyte, Inc., as Independent Non-Executive Director from 2021, BioAge Labs, Inc., as Independent Director from 2021, ALX Oncology, Inc., as Director from 2020, Hemmo Pharmaceuticals Pvt Ltd., as Director & Partner, ALX Oncology Holdings, Inc., as Non-Executive Independent Director from 2020, and Hemmo Pharma LLP, as Director & Partner. Ms. Hemrajani also formerly worked at Aravive, Inc., as President, Chief Executive Officer & Director in 2020, Jiya Acquisition Corp., as Chief Executive Officer & Director from 2020 to 2022, Adverum Biotechnologies, Inc., as Independent Director from 2019 to 2021, Lehman Brothers, Inc., as Vice President, Onyx Pharmaceuticals, Inc., as VP & Head-Licensing, Mergers & Acquisitions from 2012 to 2013, Exelixis, Inc., as Vice President-Business Development from 2003 to 2011, Sagimet Biosciences, Inc., as CFO, SVP-Business & Financial Operations from 2015 to 2016, Rapt Therapeutics, Inc., as Chief Operating Officer from 2016 to 2019, and Arcus Biosciences, Inc., as Chief Operating & Financial Officer in 2019. Ms. Hemrajani received her undergraduate degree from the University of Michigan and Masters Business Admin degree from Kellogg School of Management. |
| Patrick G. Enright |
Mr. Patrick G. Enright is an Independent Director at BioAge Labs, Inc., an Independent Director at Zenas BioPharma, Inc., an Independent Director at Vera Therapeutics, Inc., a Chairman at CuraSen Therapeutics, Inc., an Independent Director at Jazz Pharmaceuticals Plc and a Managing Director at Longitude Capital Management Co LLC. He is on the Board of Directors at BioAge Labs, Inc., Zenas BioPharma, Inc., Opna Immuno-Oncology SA, Endeavor BioMedicines, Inc, Vera Therapeutics, Inc., National Venture Capital Association, Epirium Bio, Inc., Orbus Therapeutics, Inc., Lemo USA, Inc., Jazz Pharmaceuticals Plc, InfaCare Pharmaceutical Corp. and Raven Biotechnologies, Inc. Mr. Enright was previously employed as an Independent Director by SutroVax, Inc., an Independent Director by Esperion Therapeutics, Inc., an Independent Director by CardioDx, Inc., an Independent Director by Corcept Therapeutics, Inc., a Managing Director by Pequot Ventures, a Managing Director by Pequot Capital Corp., a Senior VP-Finance & Business Development by Boehringer Mannheim Pharmaceuticals Corp., a Managing Member by Delta Opportunity Fund LLC, a Vice President by PaineWebber Development Corp., a Principal by Geneva Pharmaceuticals, Inc., a Chief Financial Officer & SVP-Business Development by Valentis, Inc., and a Chief Financial Officer & Senior Vice President by Urigen Pharmaceuticals, Inc. He also served on the board at Dascena, Inc., Rivus Pharmaceuticals, Inc., Aptinyx, Inc., Aimmune Therapeutics, Inc., Jazz Pharmaceuticals, Inc., Sequenom, Inc., Threshold Pharmaceuticals, Inc., Codexis, Inc., Horizon Therapeutics Ltd. (Ireland), MAP Pharmaceuticals, Inc., DiObex, Inc., Horizon Therapeutics, Inc., Prestwick Pharmaceuticals, Inc., Tecan Genomics, Inc. and Xanodyne Pharmaceuticals, Inc. He received his undergraduate degree from Stanford University and an MBA from The Wharton School of the University of Pennsylvania. |
